insight kol call refractori chronic cough
friday host kol call dr mandel sher univers south florida prof surind
bir king colleg hospit discuss refractori chronic cough variou therapi
develop diseas name antagonist class clinic develop
replay call found expert emphas size refractori cough
market signific unmet need non-narcot therapi effect limit
addit call address on-going debat surround role vs
chronic cough note enrol recent complet one bayer studi select
antagonist data could come earli bayer provid guidanc
provid clarif topic readthrough bellu toronto blu program
refractori chronic cough market could bigger estim multipl
epidemiolog studi note chronic cough preval dr bir believ
preval detail denmark studi use model may accur
measur diseas literatur popul kol note half
refractori current therapi would repres increas estim
patient elig receiv one chronic cough therapi develop dr sher also note
therapi approv refractori chronic cough awar diseas increas
among physician number elig patient continu rise note potenti use
cough indic well
chronic cough dramat impact patient qol kol emphas refractori
chronic cough debilit diseas underappreci gener commun chronic
cough patient consist lower score leicest cough questionnair develop
dr bir assess individu qualiti life physic psycholog social
perspect addit fatigu chest pain headach nausea femal patient
make total patient popul experi urinari incontin diseas
also link insomnia depress anxieti social embarrass
year left
short interest float
financi cad
given lack novel approv therapi last year refractory/idiopath chronic
cough remain signific unmet need outsid non-pharmacolog therapi like speech
patholog behavior therapi commonli practic physician left prescrib
sub-optim neuromodul gabapentin pregabalin slow-releas morphin eu
demonstr consist efficaci associ meaning advers event
addit insight gefapix tast effect remind merck antagonist
gefapix demonstr statist signific reduct awak cough frequenc phase iib
trial howev patient report form tast disturb complet tast
loss discontinu treatment bid due taste-rel ae experi
gefapix dr sher dr bir agre associ tast effect highli variabl
one patient next persist major subject note therapi
gener well-toler particularli given clinic efficaci fact taste-effect
revers short period time follow cessat treatment howev kol
believ chronic cough therapi remit major patient requir
prolong treatment therefor would prefer antituss agent associ
mid begin phase ii studi chronic cough
mid phase ii result chronic cough
analyst certif disclosur pleas see page
debat role vs chronic cough continu mention prior work debat
receptor main driver refractori chronic cough weve heard feedback side dr sher believ homotrim
import factor dr bir note may play import role well howev acknowledg view
specul clinic data ultim solv debat result bayer bellu present us follow distinct
main driver chronic cough base literatur bellu preclin data demonstr reduct cough frequenc guinea
pig treat convers kol would surpris heterotrim sole mechan behind
main driver chronic cough bellu preclin data literatur point possibl howev clinic data
help confirm whether hypothesi true
play role chronic cough kol consult note sinc diseas heterogen
unlik one drug work patient possibl chronic cougher react favor select antagonist
other requir therapi target well
near-term readout provid insight topic upcom phase ii data bayer select program bayer
reveal much detail characterist patent claim asset select
receptor result on-going studi would readthrough bellu program primari complet first
phase ii trial estim data could come earli bayer provid guidanc
view readout import inflect point bellu come phase ii data
upcom data readout chronic cough space addit bayer phase ii readout clinic data
expect nerr privat orvepit attenua privat bradaniclin come month orvepit receptor
antagonist assess dose-escal phase iib studi refractori cough patient trial
alreadi complet data expect orvepit shown reduc cough frequenc baselin follow-
open label phase iia studi
attenua bradaniclin neuron nicotin acetylcholin receptor nachr agonist activ subtyp gabaerg interneuron
brainstem order mitig cough phase ii studi assess safeti efficaci asset refractori chronic
cough patient expect complet
relev abstract american thorac societi at confer merck bellu health present data respect
antagonist at may shown merck detail design rational two phase studi gefapix
refractori chronic cough also present data phase ii studi ipf patient chronic cough bellu health present addit
data phase studi refractori chronic cough
session highli select homotrimer receptor antagonist improv tast safeti profil
session rational design phase random control trial gefapix
receptor antagonist refractori unexplain chronic cough
session treatment chronic cough idiopath pulmonari fibrosi patient gefapix receptor antagonist
twelve-month price target base dcf valuat assum wacc termin growth rate million fulli dilut
share pro-forma po potenti upsid model includ better expect clinic result could
requir us boost peak penetr probabl success relev indic expans addit indic
potenti success earlier anticip regulatori approv sale surpass expect patent extens
risk price target includ wors expect clinic result unforeseen competit emerg
initi target indic chang regulatori environ market downturn potenti dilut financ
alpha seri
lifesci capit alpha seri intend encompass high conviction/impact idea within healthcar sector analys
recommend base deep fundament analysi goal help creat alpha investor long run
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect secur subject
compani research analyst cover research view express report accur reflect person view
subject secur subject compani part research analyst compens directli
indirectli relat specif recommend view express research analyst report
